Financing the rising cost of haemophilia care at a large comprehensive care centre

Journal of the Royal College of Physicians of London

Volumn 31, Issue 6, 1997, Pages 640-644

  Miners, Alexander H ^a   Sabin, Caroline A ^b   Stevens, Andrew J ^b   Tolley, Keith H ^b   Lee, Christine A ^b  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR CONCENTRATE;

ARTICLE; CONTRACT; HEALTH CARE COST; HEALTH CARE FINANCING; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HUMAN; MALE; UNITED KINGDOM;

FACTOR IX; FACTOR VIII; FINANCIAL SUPPORT; GREAT BRITAIN; HEALTH CARE COSTS; HEMOPHILIA A; HEPATITIS C; HIV INFECTIONS; HUMANS; MALE; STATE MEDICINE;

EID: 0031416858     PISSN: 00358819     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Nilsson, IM. Hemophilia, Stockholm: Pharmacia, 1994.
2. UK Haemophilia Centre Directors Annual Returns (Appendix A). Oxford, 1994.
3. NHS Executive. Provision of haemophilia treatment and care. HSG(93)30. Leeds: NHSE, 1993.
4. Smith PS, Teutsch SM, Shaffer PA, Rolka H, Evatt B. Episodic versus prophylactic infusions for haemophilia A: A cost-effectiveness analysis. J Pediatr 1996;129:424-31.
5. McCarthy M. Hepatitis A linked to clotting factor in the USA. Lancet 1996; 347:251.
6. Kedda M-A, Kew MC, Cohn RJ, Field SP, et al. An outbreak of hepatitis A among South African patients with haemophilia: evidence implicating contaminated factor VIII concentrate as the source. Hepatology 1995;22:1363-7.
7. Flores G, Juárez JC, Montoro JB, Tusell JM, et al. Seroprevalance of parvovirus B19, cytomegalovirus, hepatitis A virus and hepatitis E virus antibodies in haemophiliacs treated exclusively with clotting-factor concentrates considered safe against human immunodeficiency and hepatitis C viruses. Haemophilia 1995;1:115-7.
8. Yee TT, Cohen BJ, Pasi KJ, Lee CA. Transmission of symptomatic parvovirus B19 infection by clotting factor concentrate. Br J Haematol 1996;93:457-9.
9. Lefrère J-J, Mariotti M, Thauvin M. B19 parvovirus DNA in solvent/detergent-treated anti-haemophilia concentrates. Lancet 1994;343:211-2.
10. United Kingdom Haemophilia Centre Directors Organisation Executive Committee. Guidelines on therapeutic products to treat haemophilia and other hereditary coagulation disorders. Haemophilia 1997;3:63-77.
11. Berntop E, Nilsson IM. Use of high-purity factor VIII concentrate (Hemate P) in von Willebrand's disease. Vox Sang 1989;56:212-7.
12. Allain J-P. Dose requirements for replacement therapy in haemophilia A. Thromb Haemostas 1979;42:825-31.
13. Nilsson IM, Berntop E, Löfqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992;232:25-32.
14. Aledort LM, Haschmeyer RH, Pettersson H and the Orthopaedic Outcome Study Group. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. J Intern Med 1994;236:391-9.
15. Hay CRM, Colvin BT, Ludlam CA, FGH Hill, Preston FE. Recommendations for the treatment of factor FVIII inhibitors: from the UK Haemophilia Centre Directors' Organisation Inhibitor Working Party. Blood Coag Fibrinol 1996;7:134-8.
16. Colvin BT, Hay CRM, Hill FGH, Preston FE. The incidence of factor VIII inhibitors in the United Kingdom, 1990-1993. Br J Haematol 1995;89:908-10.
17. Yee TT, Williams MD, Hill FGH, Lee CA, Pasi KJ. Absence of inhibitors in previously untreated patients with severe haemophilia A after exposure to a single intermediate purity factor VIII product. Thromb Haemostas (in press).
18. Mannucci PM. The choice of plasma-derived clotting factor concentrates. Baillière's Clin Haematol 1996;9:273-90.
19. Berntop E. Impact of replacement therapy on the evolution of HIV infection in haemophiliacs. Thromb Haemostas 1994;71:678-83.
20. Seremetis SV, Aledort LM, Bergman GE, Bona R, et al. Three-year randomised study of high-purity or intermediate purity factor VIII concentrate in symptom-free HIV seropositive hemophiliacs: effects on immune status. Lancet 1993;342:700-3.
21. Sabin CA, Pasi KJ, Philips AN, Elford JE, et al. CD4+ counts before and after switching to monoclonal high-purity factor VIII concentrate in HIV-infected haemophiliac patients. Thromb Haemostas 1994;72:214-7.
22. Kennelly JM, Tolley KH, Ghani AC, Sabin CA, et al. Hospital costs of treating haemophilic patients infected with HIV. AIDS 1995;9:787-83.
23. Kernoff PB, Lee CA, Karayiannis P, Thomas HC. High risk of non-A non-B hepatitis after first exposure to volunteer or commercial clotting factor concentrates: effects of prophylactic immune serum globulin. Br J Haematol 1985;60:469-79.
24. Telfer P, Sabin C, Devereux H, Scott F, et al. The progression of HCV-associated liver disease in a cohort of haemophilic patients. Br J Haematol 1994;83:555-61.
25. Varagona G, Brown D, Kibbler H, Scheuer P, et al. Response, relapse and retreatment rates and viraemia in chronic hepatitis C treated with α2b interferon. A phase III study. Eur J Gastroent Hepatol 1992;4:707-12.
26. Dusheiko GM. Management of chronic hepatitis C. Haemophilia 1995; 1(suppl 4):30-5.
27. NHS Executive. National Specialist Commissioning Advisory Group: Letter To Purchasers. EL(97)9. Leeds: NHSE, 1997.
28. Szucs TD, Öffner A, Schramm W. Socioeconomic impact of haemophilia care: results of a pilot study. Haemophilia 1996; 2:211-7.
29. Sculpher M, Drummond M, Buxton M. Economic evaluation in health care research and development: undertake it early and often. HERG discussion paper No. 12. Uxbridge: Brunel University, 1995.
30. Sculpher M, Drummond M, Buxton M. The iterative use of economic evaluation as part of the process of health technology assessment. J Health Serv Res Policy 1997;2:26-30.
31. Martinowitz UP, Schulman S. Continuous infusion of factor concentrates: review of use in haemophilia A and demonstration of safety in haemophilia B. Acta Haematol 1995;94 (suppl 1):35-42.
32. Schulman S, Gitel S, Varon D, Martinowitz U. Studies on safety and efficacy of continuous infusion with coagulation factor concentrates. Sem Haematol 1994;31(suppl 2):57-61.
33. Schulman S, Martinowitz U. Concentrate infusion instead of bolus injections of factor concentrate? Haemophilia 1996;2:189-91.
34. Peake I. The role of gene therapy in haemophilia. Haemophilia 1995;1(suppl 1):40-3.
35. Pasi KJ. Gene therapy for haemophilia. Baillière's Clin Haematol 1996;9:305-17.
36. Bontempo FA, Lewis JH, Gorenc TJ, Spero AJ, et al. Liver transplantation in hemophilia A. Blood 1987;68:1721-4.